Quality of life There were no major statistically significant ; differences in QoL between oral capecitabine and 5-FU LV from baseline to 25 weeks of trial treatment no statistical data reported however, other studies suggest that patients prefer oral chemotherapy to intravenous treatment. Adverse events toxicities ; As a result of toxicity, both groups required dose modifications, interruptions and delays.
Proteins using anti-RSV serum. Since both F317 and F313 could be recognized by immunoprecipitation with the polyclonal anti-RSV serum Fig. 1, and 4 to 8 ; , but not by indirect immunofluorescence, we concluded that SDS treatment of uncleaved F protein was required for antibody recognition. These data suggested that aberrant folding was responsible for the lack of intracellular recognition of F313 by the F protein-specific antibodies because only SDS-denatured proteins were immunoreactive. Therefore, immunoprecipitation of SDS-treated F glycoproteins was our only means of comparing the maturation and transport of the cleaved and uncleaved F glycoproteins in subsequent experiments.

Data ; , whose expression is upregulated in osteoarthritis 39 ; . There, versican may form aggregates with LP and HA, and the versican aggregate may have distinct function from the aggrecan aggregate. Further studies on the structure and in vivo function of these aggregates remain to be performed and capsicum. RNR is composed of two subunits, R1 and R2. GTI-2040 and GTI-2501 target the R2 and R1 subunits of human RNR, respectively, which are required for DNA synthesis and tumor cell growth. RNR activity is elevated in a wide range of tumors. In addition, the R2 component appears to act as a signal molecule in cancer cells and increases the activity of a biochemical pathway that plays an important role in tumor progression. Both GTI-2040 and GTI-2501 have shown sequence target specificity for each target in vitro and in vivo, and exhibit effective anti-tumor activity in a broad spectrum of human cancers in mouse models, including, lung, breast, colon, kidney, ovarian, pancreatic, skin, prostatic, and cervical cancers. Positive results that have been demonstrated include significant tumor growth inhibition, disease stabilization, and tumor regression. Toxicology studies in rodents and monkeys of GTI-2040, and preliminary results with GTI-2501, indicate that these compounds are likely to be safe in humans at concentrations that exceed therapeutic doses. GTI-2040 targets the R2 component of RNR, a novel malignant determinant that can cooperate with a type of cancer causing genes, known as oncogenes. Preclinical animal models have demonstrated that GTI-2040 has particular efficacy in inhibiting tumor growth in animal tumor models of RCC, alone or in combination with other agents. GTI-2040 received approval of its Investigational New Drug IND ; application in 1999 and entered a Phase I clinical trial in June 2000 at the University of Chicago Cancer Research Center. GTI-2501 has shown complete tumor regression in mice containing human breast cancer and human kidney cancer cells. The FDA approved an IND for Phase I clinical trials in February 2001 for use on patients with solid tumors or lymphoma. GTI-2040 Combined with Capecitabine Xeloda ; for Treating Advanced Renal Cell Carcinoma RCC ; RCC is a devastating disease with a high mortality rate and restricted therapeutic options. Immunotherapies have been used with very limited success in a subset of patients. One of the primary barriers to the efficacy of these therapies has been the number of serious toxicity concerns that have precluded their therapeutic usefulness. RCC is the most common type of kidney cancer, with more than 190, 000 cases diagnosed annually throughout the world. The majority of patients are over the age of 40. More than 90, 000 patients die annually from this disease worldwide and the age-adjusted world incidence has been increasing steadily at an annual rate of approximately 2%. Advanced RCC is typically resistant to chemotherapy, with reported response rates of less than 10%. Current immunotherapeutic treatments include the cytokines, interferon, and interleukin-2. Tumor response rates for these agents are low, however, in the range of 15%. GTI-2040 is being studied in clinical trials in combination with capecitabine Xeloda from Roche Holdings ; for the treatment of advanced RCC in patients who have failed previous chemotherapies. Capecitabine is a well-known oral anti-cancer treatment. The design of the trial was developed by Dr. Walter Stadler of the University of Chicago, who has published extensively on the subject of treatments for RCC. In January 2004, interim data were analyzed from the Phase II clinical trial of GTI-2040 in combination with capecitabine for patients with advanced RCC. The majority of patients had failed two or more prior therapies before entering the study, exhibited extensive metastases, and were representative of a population with a very poor prognostic outcome. In August 2004, Lorus announced findings from the dose escalation stage of its Phase II clinical trial of GTI-2040 and capecitabine in metastatic kidney cancer patients at seven test sites in the U.S. These findings demonstrated that GTI-2040 was well tolerated in combination with capecitabine, with no reduction in the starting capecitabine dose required, up to and including the target GTI-2040 dose that was previously established as a monotherapy in a Phase I clinical investigation. The clinical findings were presented in August 2004 by Dr. Apurva Desai, an oncology investigator at the University of Chicago, at the First International Congress on Kidney and Bladder Cancer, held in Orlando, FL. A Phase II III registration clinical program for GTI-2040 in RCC is presently being designed. QUES T IONS P LE A IRC L E A NSW ER ; : 1. The German rectal study presented at the 2003 ASTRO meeting demonstrated that compared to postoperative chemoradiation, preoperative chemoradiation resulted in: a. A significant decrease in local recurrence b. A significant decrease in acute and long-term toxicity c. An improved sphincter preservation rate d. All of the above 2. NSABP-R-04 is a preoperative trial comparing capecitabine plus radiation therapy to: a. Bolus 5-FU leucovorin plus radiation b. Capecitabine oxaliplatin plus radiation c. Continuous infusion 5-FU plus radiation d. None of the above 3. The X-ACT adjuvant study of colon cancer compares the Mayo Clinic regimen to capecitabine. a. True b. False 4. The experimental arm in the MOSAIC adjuvant study was: a. FOLFOX7 b. FOLFOX6 c. FOLFOX4 d. CAPOX e. None of the above 5. NSABP-R-03, comparing preoperative versus postoperative chemoradiation therapy, failed to meet its target accrual. a. True b. False 6. NSABP-C-09 will evaluate with and without hepatic arterial infusion floxuridine after resection or ablation of liver metastases. a. Capecitabine plus irinotecan CAPIRI ; b. Capecitabine plus oxaliplatin CAPOX ; c. Irinotecan plus oxaliplatin IROX ; d. None of the above 7. In the Memorial Sloan-Kettering Cancer Center's experience, the addition of dexamethasone to HAI floxuridine decreased bilirubin levels but had no effect on response rate and survival. a. True b. False 8. In the Intergroup randomized trial in patients with liver metastases, compared to 5-FU leucovorin, HAI floxuridine resulted in: a. A higher objective response rate b. A longer median survival c. A longer time to hepatic progression d. All of the above 9. The Phase III trial presented at the 2003 ASCO meeting of first-line IFL bevacizumab versus IFL, and the ECOG-2200 Phase II study of IFL bevacizumab both demonstrated prolonged survival with the addition of bevacizumab in patients with metastatic colorectal cancer. a. True b. False 10. A unique feature of ECOG-3201, a Phase III adjuvant study in which patients with Stage II or III rectal cancer are randomly assigned to one of three different chemotherapy regimens, is that the treating physician rather than the protocol ; decides whether the patient receives chemoradiation before or after surgery. a. True b. False and carbachol. 1. Herbst RS, Bajorin DF, Bleiberg H et al. Clinical cancer advanced 2005: major research advanced in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology. J Clin Oncol 2006; 24: 190205. Burris HA, Moore MJ, Andersen J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 24032413. Heinemann V. Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials. Semin Oncol 2002; 29 Suppl 20 ; : 916. 4. Moore MJ, Goldstein D, Hamm J et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinicals trials group [NCIC-CTG]. Proc Soc Clin Oncol 2005; 23: Abstr 1 ; . 5. Cunningham D, Chau I, Stocken D et al. Phase III randomised comparison of gemcitabine GEM ; versus gemcitabine plus capecitabine GEM-CAP ; in patients with advanced pancreatic cancer. Eur J Cancer Suppl 2005; 3: Abstr PS11 ; . 6. Oettle H, Pelzer U, Stieler J et al. Oxaliplatin folinic acid 5-fluorouracil [24h] OFF ; plus best supportive care versus best supportive care alone BSC ; in second-line therapy of gemcitabine-refractory advanced pancreatic cancer CONKO 003 ; . Proc Soc Clin Oncol 2005; 23: Abstr 4031 ; . 7. Tsavaris N, Kosmas C, Skopelitis H et al. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: a phase II study. Invest New Drugs 2005; 23: 369375. Cantore M, Rabbi C, Fiorentini G et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004; 67: 9397. Demols A, Peeters M, Polus M et al. Gemcitabine and oxaliplatin GEMOX ; in gemcitabine refractory advanced pancreatic adenocarcinoma: a phase II study. Br J Cancer 2006; 94: 481485. Reni M, Pasetto L, Aprile G et al. Raltitrexed-eloxantin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer. Br J Cancer 2006; 94: 785791. Oettle H, Arnold D, Esser M et al. Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma. Anticancer Drugs 2000; 11: 635638. Milella M, Gelibter A, Di Cosimo S et al. Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma. Cancer 2004; 101: 133138. Jacobs AD, Burris HA, Rivkin S et al. A randomized phase III study of rubitecan ORA ; vs. best choice BC ; in 409 patients with refractory pancreatic cancer. Report from a North-American multi-center study. Proc Soc Clin Oncol 2004; 22: Abstr 4013 ; . 14. Ulrich-Pur H, Ruderer M, Kornek GV et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003; 88: 11801184. Blaszkowsky LS, Kulke KH, Ryan DP et al. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer. Proc Soc Clin Oncol 2005; 23: Abstr 4099 ; . 16. Shih C, Chen VJ, Gossett LS et al. LY231514, a pyrrolo[2, 3-d]-pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 11161123. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 26362644.

Xeloda capecitabine ; tablets and carbenicillin.
Capecitabine 1250 mg m2 twice daily in 3-week cycles 2 weeks of treatment followed by a 1-week rest period ; 5-FU LV in Mayo clinic regimen: rapid i.v. injection of 20 mg m2 LV followed by an i.v. bolus injection of 425 mg m2 5-FU daily, days 15 every 4 weeks.

Successful it was pivotal to perform the whole procedure within a week; otherwise the enzyme deteriorated quickly. For this purpose we employed high performance liquid chromatography for ion-exchange chromatography and installed a thin layer chromatogram scanner which allowed to monitor us radioactivity on thin layer plates much faster than before. Once the enzyme was purified it was stable at least for 1week when stored in the cold. Although it has been already reported 27-hydroxylase exists in that 5~-cholestane-3a, 7au, 12a-triol liver mitochondria 2-9 ; , this has now been fully confirmed by the present experiment. The purified enzyme showed cho and carboplatin.

1548 2716.00.00.00 Electrical energy. 28.01 Fluorine, chlorine, bromine and iodine. I. CHEMICAL ELEMENTS 1549 2801.10.00.00 -Chlorine 1550 2801.20.00.00 -Iodine 1551 2801.30.00.00 -Fluorine; bromine 1552 2802.00.00.00 Sulphur, sublimed or precipitated; colloidal sulphur. 28.03 Carbon carbon blacks and other forms of carbon not elsewhere specified or included ; . -Rubber grade carbon black -Acetylene black -Other carbon blacks -Other and carmustine. Capecitabine is contraindicated in patients who have severe renal impairment, dpd deficiency, or who are pregnant or breastfeeding. It’ s basically doctor’ s choice — cmf or ac versus capecitabine — for women who are older than 65 years of age and have operable breast cancer and carteolol. Mae'r Sefydliad Cenedlaethol dros Ragoriaeth Glinigol NICE ; yn rhan o'r GIG. Mae'n cynhyrchu arweiniad ar gyfer y GIG a chleifion ar ddefnyddio meddyginiaethau, offer meddygol, profion diagnostig a gweithdrefnau clinigol a llawfeddygol ac o dan pa amgylchiadau y dylid eu defnyddio. I gynhyrchu'r arweiniad hwn, mae NICE yn ystyried pa mor dda y mae'r feddyginiaeth, yr offer neu'r weithdrefn yn gweithio a hefyd pa mor dda y mae'n gweithio o'i gymharu 'r gost. Gelwir y broses hon yn arfarniad. Mae'r broses o arfarnu yn cynnwys gweithgynhyrchydd y feddyginiaeth neu'r offer y llunnir yr arweiniad ar ei gyfer, a'r sefydliadau sy'n cynrychioli'r gweithwyr gofal iechyd proffesiynol, y cleifion a'u gofalwyr y bydd yr arweiniad yn effeithio arnynt. Bydd pob arfarniad yn cymryd tua 12 mis i'w gwblhau. Gofynnwyd i NICE edrych ar y dystiolaeth sydd ar gael y meddyginiaethau capecitabine a thegafur gydag uracil a rhoi arweiniad a fyddai'n helpu'r GIG yng Nghymru a Lloegr i benderfynu pryd y dylid eu defnyddio ar gyfer pobl sydd chanser colorefrol metastatig. Because of the toxicity in the capeox arm, the dose of capecitabine was lowered to 850 mg m 2 in the tree-2 study and caverject.

14 Table 2.2 Properties of high performance fibers in reinforced polymers [12] Ultimate Tensile Strength, GPa ; 3.60 4.50 2.30 Tensile Modulus GPa ; 76 86 200 Specific Tensile Strength GPa ; 1.40 1.80 1.26 Specific Modulus GPa ; 29 34 110. Capecitabine in Metastatic Colorectal Cancer removed and stored in plastic tubes below 20 C until analysis. Urine was collected and pooled during the following time intervals: 0, 011 and 1124 h on day 1; and 011 h on day 14. At the end of each interval, the total volume and the pH of urine were recorded; and a 15 ml aliquot was removed and stored at 20 C until analysis. Plasma and urine concentrations of capecitabine and its metabolites were determined by a validated liquid chromatography with mass-spectrometry detection LC MS-MS ; . The lower limits of quantification LLOQ ; of capecitabine, 50 -DFCR, 50 -DFUR, 5-FU and a-fluoro-b-alanine FBAL ; in plasma were 0.01, 0.05, and 0.011 mg ml, respectively. The LLOQ of capecitabine, 50 -DFCR, 50 -DFUR, 5-FU, a-fluoro-b-ureidopropionic acid and FBAL in urine were 0.02, and 0.1 mg ml, respectively. Pharmacokinetic parameters were assessed by standard non-compartment analysis, using WinNonlin professional version 4.1 Pharsight Corporation ; . Maximum plasma concentration Cmax ; and the time to reach Cmax Tmax ; were determined. Apparent half-life t1 2 ; was estimated from ln2 l, where the apparent rate constant of elimination, l, was estimated by linear regression on the logarithm of the plasma concentration versus time data. The area under the plasma concentration time curve from time 0 to infinity AUC ; was estimated from the sum of AUC0t and Ctlast l, where AUC0t is the area under the curve from time 0 to the last sampling time tlast ; at which a concentration above the limit of quantification was measured Ctlast ; . AUC0t was estimated using the linearlog trapezoidal rule. Percentage of dose recovered in urine as capecitabine or one of its metabolites was calculated based on the dose administered, urinary concentration and volume of urine collected and cefazolin.
The Commission began consideration of matters falling within the Railroad Commission's Oil and Gas regulatory jurisdiction. A. The Commission took the following action on applications appearing on the protested docket of the Oil and Gas Division: 1. In consideration of Docket No. 05-0238429, the Commission approved the application of XTO Energy, Inc., to construct and operate a Hydrogen Sulfide gas pipeline and facility to be known as the Teague Townsite Compressor Station Low Pressure Suction Line, in Freestone County, Texas. Approval was recommended by Examiner Margaret Allen. The Commission considered Oil and Gas Docket Nos. 01-0234538, 01-0234543, 01-0234544, and 01-0235845, the applications of CalTex Energy Co. for exceptions to Statewide Rule 21 to produce by swabbing, bailing or jetting 157 wells on 36 leases, Stapes, Dale McBride, Buchanan, Dunlap, Darst Creek Buda ; Tenney Creek, Spiller, and Lytton Springs Fields, Caldwell and Guadalupe Counties, Texas. The Commission heard comments from Mr. John Soule, representing CalTex Energy Co. Commissioner Williams made a motion to add a condition recommended by Mr. Soule to the order. The motion died for lack of a second. Commissioner Matthews made a motion to approve the examiner's recommendation. This motion also failed for lack of a second. On motion of Chairman Carrillo, the Commission voted 3-0 ; to approve the examiner's recommendation with one condition relating to the plugging fund. Examiner Doherty stated he would need additional time to work on the technical language of the plugging fund condition and prepare a revised order to be presented at the next conference.

Sex Age y ; Previous chemotherapy regimens for metastastic disease Anti-EGFR treatment Tumor response Best response M M M FOLFIRI NA NA NA LV5FU2, FOLFOX, capecitabine and mitomycin, capecitabine and irinotecan, irinotecan LV5FU2 IV and oxaliplatin IAH, FOLFOX IV and Adriamycin IAH, FOLFIRI, irinotecan LV5FU2, LV5FU2 IV and oxaliplatin IAH, FOLFIRI, capecitabine and irinotecan LV5FU2, FOLFOX, raltitrexed and oxaliplatin, FOLFIRI, phase I trial, capecitabin and mitomycin FOLFIRI, FOLFOX, irinotecan, FOLFOX, FOLFIRI LV5FU2 IV and oxaliplatin IAH, FOLFOX, FOLFIRI FOLFIRI, FOLFIRI IV and oxaliplatin IAH, irinotecan FOLFOX, FOLFIRI LV5FU2, FOLFIRI, FOLFOX raltitrexed and oxaliplatin, raltitrexed and irinotecan FOLFOX, FOLFIRI, irinotecan FOLFOX FOLFOX, FOLFIRI FOLFIRI, FOLFOX FOLFIRI, oxaliplatin and capecitabine LV5FU2 and oxaliplatin and irinotecan, FOLFIRI LV5FU2, FOLFOX, FOLFIRI IV and oxaliplatin IAH LV5FU2 and oxaliplatin and irinotecan, irinotecan FOLFOX, FOLFIRI, raltitrexed and oxaliplatin, capecitabine, irinotecan FOLFIRI, FOLFOX FOLFOX, FOLFIRI FOLFOX, FOLFIRI, LV5FU2 and mitomycin, FOLFOX, phase I trial LV5FU2, FOLFOX, FOLFIRI capecitabine and oxaliplatin FOLFIRI, FOLFOX, irinotecan Cetuximab Cetuximab Cetuximab Cetuximab Cetuximab and and and and and irinotecan FOLFIRI FOLFIRI FOLFIRI irinotecan CR PR PR Duration wk ; 58.1 34.1 33.9 WT WT WT 2.6 KRAS mutation PIK3CA mutation EGFR copy number and ceftriaxone.
About xelox an abbreviation for a type of combination chemotherapy used to treat colorectal cancer; it contains xeloda capecitabine ; plus oxaliplatin. Scalable Performance Data Server provides ODBC, JDBC, htmSQL, and SQL C API access to SPD Server data stores from all supported platforms. SPD Server can read tables exported from Base SAS software using PROC COPY, and, with the proper drivers installed on the network, allows queries on the tables from client machines that do not have SAS software. There are four possible options. Protein-bound fraction. Hypocapnia-induced hypokalemia is usually minor. Respiratory alkalosis is the most common acid-base disturbance encountered in critically ill patients, and, when severe, it portends a poor prognosis. Many cardiopulmonary disorders manifest respiratory alkalosis in their early to intermediate stages. Hyperventilation usually results in hypocapnia. The finding of normocapnia and hypoxemia may herald the onset of rapid respiratory failure and should prompt an assessment to determine whether the patient is becoming fatigued. Respiratory alkalosis is a common occurrence during mechanical ventilation. The causes of respiratory alkalosis are summarized in Table 20-6 left column ; . The hyperventilation syndrome may mimic a number of serious conditions and can be disabling. Paresthesias, circumoral numbness, chest wall tightness or pain, dizziness, inability to take an adequate breath, and, rarely, tetany may themselves be sufficiently stressful to perpetuate a vicious cycle. Arterial blood gas analysis demonstrates an acute or chronic respiratory alkalosis, often with hypocapnia in the range of 15 to and no hypoxemia. Central nervous system disease or injury can produce several patterns of hyperventilation with sustained arterial PaCO2 levels of 20 to Hg. Conditions such as hyperthyroidism, high caloric loads, and exercise raise the basal metabolic rate, but usually ventilation rises in proportion so that arterial blood gases are unchanged and respiratory alkalosis does not develop. Salicylates, the most common cause of drug-induced respiratory alkalosis, stimulate the medullary chemoreceptor directly. The methylxanthine drugs, theophylline and aminophylline, stimulate ventilation and increase the ventilatory response to carbon dioxide. High progesterone levels increase ventilation and decrease the arterial PaCO2 by as much as 5 to Hg. For this reason, chronic respiratory alkalosis is an expected feature of pregnancy. Respiratory alkalosis is a prominent feature in liver failure, and its severity correlates well with the degree of hepatic insufficiency and mortality. Respiratory alkalosis is common in patients with gram-negative septicemia, and it is often an early finding, before fever, hypoxemia, and hypotension develop. It is presumed that some bacterial product or toxin acts as a respiratory center stimulant, but the precise mechanism remains unknown. The diagnosis of respiratory alkalosis requires measurement of arterial pH and PaCO2 which are higher and lower than normal, respectively ; . The plasma potassium concentration is often reduced, and the serum chloride concentration increased. In the acute phase, respiratory alkalosis is not associated with increased renal bicarbonate excretion, but within hours net acid excretion is reduced. In general, the bicarbonate concentration falls by 2.0 mEq L for each 10 mm Hg decrease in PaCO2. Chronic hypocapnia reduces the serum bicarbonate concentration by 5.0 mEq L for each 10 mm Hg decrease in PaCO2. It is unusual to observe a plasma bicarbonate concentration lower than 12 mEq L as a result of a pure respiratory alkalosis. When a diagnosis of hyperventilation or respiratory alkalosis is made, its cause should be investigated. The diagnosis of hyperventilation syndrome is made by exclusion. In difficult cases, it may be important to rule out other conditions such as pulmonary embolism, coronary artery disease, and hyperthyroidism!

Risk which may impede the achievement of our Price Target This report was prepared for general circulation and does not provide investment recommendations specific to individual investors. As such, the financial instruments discussed in this report may not be suitable for all investors and investors must make their own investment decisions based upon their specific investment objectives and financial situation utilizing their own financial advisors as they deem necessary. Past performance of the financial instruments recommended in this report should not be taken as an indication or guarantee of future results. The price, value of, and income from, any of the financial instruments mentioned in this report can rise as well as fall and may be affected by changes in economic, financial and political factors. If a financial instrument is denominated in a currency other than the investor's home currency, a change in exchange rates may adversely affect the price of, value of, or income derived from the financial instrument described in this report. In addition, investors in securities such as ADRs, whose values are affected by the currency of the underlying security, effectively assume currency risk.
Have shown stimulation of ascorbate synthesis after drug administration see, for example, refs. 22-25 ; . The mechanism by which inhibition of glutathione synthesis leads to stimulation of ascorbate synthesis in mouse liver is presently unknown. This mechanism may possibly be similar to one involved in drug-induced ascorbate synthesis. Although this pathway is, of course, not available to humans and guinea pigs, it would be of interest to elucidate the nature of the chemical signal by which a decrease in glutathione triggers ascorbate synthesis. Several intriguing mechanisms can be envisaged to explain how oxidative effects might trigger ascorbate synthesis. HFS is also known as palmar-plantar erythrodysesthesia PPE ; . It is localized cutaneous side effect associated with many chemotherapy agents. Fifty-six percent of patients receiving treatment with capecitabine will develop PPE. In patients receiving protracted infusions of 5-FU the incidence of PPE is 34%. Although this is not generally a.

5. TJ is y.o. premenopausal woman presenting with newly diagnosed left breast cancer. She has noticed a mass in her left breast for some time, but has neglected to have it checked out. She now comes in with dimpling of the skin of the breast, erythema, and palpable lymph nodes in the axilla and supraclavicular areas on the left. She undergoes biopsy of this mass and staging and is found to have an invasive ductal carcinoma, ER PR-negative, HER2 positive by FISH, Ki-67 60% with axillary and supraclavicular involvement and also bone metastases and questionable lung metastases. What would be the most appropriate therapy for TJ at this time? a. b. c. Docetaxel 75 mg m2 IV over 1 hour plus Carboplatin AUC 6 over 30 minutes plus Trastuzumab 4 mg kg loading dose followed by 2 mg kg weekly. Paclitaxel 175 mg m2 IV over 3 hours Q 21 days plus Trastuzumab 4 mg kg loading dose followed by 2 mg kg weekly. Bevacizumab 10 mg kg IV over 90 minutes Q 2 weeks plus Trastuzumab 4 mg kg loading dose followed by 2 mg kg weekly. Capecitabine 2500 mg m2 day PO divided BID x 14 days Q 21 days plus Trastuzumab 4 mg kg loading dose followed by 2 mg kg weekly.